About: Admin

Recent Posts by Admin

Pediatric Chronic Kidney Disease Study in Georgia

A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of a study drug for Oral Suspension in Children and Adolescents (2 to < 18) with Chronic Kidney Disease has been approved at 5 sites in Georgia. AmeRuss will be cooperating with another multinational CRO as a part...
more

AmeRuss launches Phase III Growth Hormone Deficiency Study

AmeRuss is launching a phase III multinational study in prepubertal children with growth hormone deficiency (GHD). As part of a global team, AmeRuss will be responsible for initiating 7 sites in Georgia, Armenia, and Belarus. In these 3 sovereignties, AmeRuss will provide full service support for the study conduct....
more

International Hypertension Program Launch

Medical Device clinical study in treatment of uncontrolled hypertension – an international program launch AmeRuss recently executed an agreement with a medical device firm within  an international consortium of companies to conduct a clinical trial in patients with uncontrolled hypertension. The 2 year study will combine efforts of sites in Russia, Belgium, Germany, Hungary, Ireland, Israel,...
more

Phase III study – Acute Bronchitis submitted for approval in Russia

A randomized prospective comparative, open, parallel group clinical study of the efficacy and safety of film-coated pills and oral solution of investigational drug in adults with acute bronchitis has recently been submitted to the Russian Ministry of Health for approval. AmeRuss is providing full-service regulatory and investigational support including performance of all necessary regulatory activities, submissions...
more

Interim analysis enrollment target reached on time in Phase II breast cancer study

AmeRuss is happy to announce that the global enrollment of the study of approved combination of study drugs for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer which has progressed following prior therapy reached its interim analysis milestone on time. This is an open label, randomized, multicenter, phase II study...
more

Enrollment goal reached in cardiology device study

AmeRuss is pleased to announce that 238 patients were enrolled recently in an international cardiology medical device study. This study of the efficacy and safety of sirolimus coronary stent as compared to the everolimus coronary stent  is a prospective, randomized, multicenter trial. AmeRuss Clinical Trials, LLC is providing full regulatory and investigational support including performance of all...
more

Patients with cardiac pacemakers- Remote Monitoring Technology

Advances in information and telecommunication technology has led to the birth of a radically new medical service based on the remote mobile monitoring of patients with implanted pacemakers, defibrillators, or cardiac resynchronization devices. This medical device study managed by AmeRuss is designed to evaluate clinical and economic benefits from monitoring of the patient`s condition with the...
more

Global enrollment goal reached in Phase II Severe Asthma Study

Nov 2015. The global enrollment goal of 544 subjects in this study has been reached. The aim of the study is to evaluate the efficacy and safety of mepolizumab adjunctive therapy on markers of asthma control in subjects with severe eosinophilic asthma. The international study is a randomized, double-blind, placebo-controlled, parallel-group, multi-center. Recruitment for the study has...
more

AMERUSS CLINICAL TRIALS ATTENDS BIOCOM’s Annual Open House & Supplier Showcase

San Diego, CA, July 25, 2013

BIOCOM is the largest regional life science association in the world, representing more than 550 member companies in Southern California. The association focuses on initiatives that positively influence the region’s biotechnology and medical device community. AmeRuss Clinical Trials, LLC is a proud member participant of this event.  Thought leaders from...
more

Recent Comments by Admin

    No comments by Admin yet.